The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.

Start Date01 Oct 2026

Sponsor / Collaborator

VA Office of Research and Development

NCT07425990

/ Not yet recruitingNot ApplicableIIT

FET-LET-2x2: A Randomized Open-Label 2×2 Factorial Trial Comparing Clinical Pregnancy Rates After Frozen Embryo Transfer in True and Modified Natural Cycles With and Without Aromatase Inhibitors

The goal of this clinical trial is to learn whether different natural approaches to preparing the uterus for frozen embryo transfer (FET) can improve pregnancy success in women undergoing in vitro fertilization (IVF) treatment.
The main questions it aims to answer are:
1. Is a completely natural menstrual cycle more successful than a natural cycle in which ovulation is triggered with medication when preparing for frozen embryo transfer?
2. Does taking a medication called letrozole at the beginning of the cycle improve pregnancy success compared to not taking it?
Researchers will compare four different approaches to see which one results in the highest chance of achieving a clinical pregnancy, confirmed by ultrasound.
Participants will:
* Be randomly assigned to one of four groups
* Undergo monitoring with ultrasound and blood hormone tests during their menstrual cycle
* In some groups, take letrozole tablets for a few days early in the cycle
* In some groups, receive a hormone injection to help control the timing of ovulation
* Undergo frozen embryo transfer at the appropriate time
* Receive standard hormonal support after embryo transfer
* Researchers will compare four different approaches to see which one results in the highest chance of achieving a clinical pregnancy, confirmed by ultrasound.

Start Date01 Feb 2026

Sponsor / Collaborator

University of Novi Sad

NCT07108621

/ RecruitingPhase 3IIT

Eight Weeks of Low Dose hCG Priming in Women With Diminished Ovarian Reserve Undergoing IVF/ICSI - a Randomized Controlled Trial

The aim of this randomized controlled trial is to further examine the possible effects of low dose human chorionic gonadotropin (hCG) priming for eight weeks in women with diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The investigators want to retest the findings of our first study in an identical paired design (NCT04643925), as an increase of 1.5 in mean number of oocytes retrieved is clinically relevant. To incorporate the strengths of a randomized controlled trial design, women will be randomized after their first ICSI treatment to receive either hCG or placebo in a double-blinded design during an eight-week priming period preceding their second ICSI treatment. The primary outcome is the number of oocytes retrieved in the second ICSI treatment.

Start Date01 Sep 2025

Sponsor / Collaborator

Rigshospitalet

[+2]

100 Clinical Results associated with Choriogonadotropin alfa

100 Translational Medicine associated with Choriogonadotropin alfa

100 Patents (Medical) associated with Choriogonadotropin alfa

263

Literatures (Medical) associated with Choriogonadotropin alfa

01 Mar 2026·FERTILITY AND STERILITY

Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial

Article

Author: Rodriguez, Ignacio ; Polyzos, Nikolaos P ; García-Martinez, Sandra ; Neves, Ana Raquel ; Donno, Valeria

OBJECTIVE:

The study aimed to compare the efficacy, in terms of mature oocytes, of dual trigger vs. agonist alone in good-prognosis patients undergoing elective fertility preservation.

DESIGN:

Randomized, controlled, single-center, superiority clinical trial.

SUBJECTS:

A total of 109 women were enrolled in this study between October 2021 and April 2023 with a 1:1 allocation. Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.

INTERVENTION:

Controlled ovarian stimulation was performed using 225-300 IU/d of follitropin α or β or 15-20 μg of follitropin δ, tailored to ovarian reserve and weight. Luteinizing hormone surge was suppressed through a progestin-primed ovarian stimulation protocol, with oral administration of micronized progesterone (200 mg daily) from the beginning of ovarian stimulation until the trigger day. As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).

MAIN OUTCOME MEASURES:

The primary endpoint was the number of metaphase II (MII) oocytes retrieved after final oocyte maturation with dual trigger and GnRH-a trigger in patients undergoing elective fertility preservation.

RESULTS:

Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a). No statistically significant differences were found regarding the total number of oocytes nor MII oocytes retrieved between the dual trigger and GnRH-a groups (9.22 ± 5.11 vs. 9.56 ± 5.16 [estimated mean difference, -0.34 {95% confidence interval, -2.29 to 1.61}] and 7.31 ± 4.63 vs. 7.94 ± 4.39 group [estimated mean difference, -0.64 {95% confidence interval, -2.07 to 0.80}], respectively). Likewise, no statistically significant differences were found regarding estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone levels on the day after the trigger. Notably, neither group exhibited any case of ovarian hyperstimulation syndrome.

CONCLUSION:

In patients undergoing fertility preservation, adding human chorionic gonadotropin to GnRH-a for triggering final oocyte maturation is not superior to the administration of GnRH-a alone in terms of MII oocytes. Therefore, the selection of the trigger method should be based on both patients' and clinicians' preferences, with a focus on patients' safety and convenience.

01 Feb 2026·REPRODUCTIVE BIOMEDICINE ONLINE

Mid-luteal serum progesterone concentrations in modified natural cycles for embryo transfer: a prospective blinded study

Article

Author: Gómez, Víctor H ; Rodríguez-Varela, Cristina ; Cruz, Fabio ; Remohí, José ; Olmo, Inés ; Bellver, José ; Romero, Pep ; Alamá, Pilar ; Paolelli, Stefania ; Labarta, Elena ; Bosch, Ernesto ; Marzal, Alicia ; Doblinger, Jakob ; Vidal, Carmina ; Giles, Juan

RESEARCH QUESTION:

Does mid-luteal serum progesterone concentration influence pregnancy outcomes in modified natural cycle frozen embryo transfer (mNC-FET) with ovulation triggering and luteal phase support (LPS)?

DESIGN:

This prospective, blinded, single-centre cohort study was conducted at IVIRMA Valencia (Spain) between February 2020 and June 2021. A total of 241 infertile patients under 50 years old, with body mass index (BMI) <40 kg/m², undergoing mNC-FET were included. Ovulation was triggered with recombinant human chorionic gonadotrophin when the dominant follicle measured ≥16 mm and endometrial thickness was >6.5 mm. LPS was provided with micronized vaginal progesterone 200 mg every 12 h. Serum progesterone was measured within 2 h of embryo transfer, and results were blinded until study completion.

RESULTS:

Mean serum progesterone on embryo transfer day was 26.2 ± 9.0 ng/ml, with 99% of patients exceeding the clinically relevant threshold (>10 ng/ml). Participants were stratified into quartiles by progesterone concentration, with no significant differences in ongoing pregnancy rates: Q1 (<20.2 ng/ml), 56.7%; Q2 (20.2-24.8 ng/ml), 47.5%; Q3 (24.9-31.1 ng/ml), 51.7%; Q4 (>31.1 ng/ml), 48.3% (P = 0.74). Live birth rates were also comparable (P = 0.66). In multivariable logistic regression, mid-luteal serum progesterone was not significantly associated with ongoing pregnancy (odds ratio 0.86, 95% CI 0.40-1.85; P = 0.70) after adjusting for clinical covariates. Female age, oocyte age, BMI, number of previous transfers, embryos transferred, embryo quality, and oocyte origin were also unrelated to pregnancy probability.

CONCLUSIONS:

In mNC-FET cycles with HCG triggering and LPS, mid-luteal serum progesterone concentrations were consistently adequate and not associated with pregnancy outcomes. Routine progesterone monitoring appears unnecessary in this setting.

01 Feb 2026·JOURNAL OF ASSISTED REPRODUCTION AND GENETICS

2,000 IU hCG is the optimal dose in a dual hCG/GnRH agonist trigger to achieve comparable pregnancy rates to hCG alone in fresh embryo transfers

Article

Author: Lanes, Andrea ; Oliva, Margeaux ; Yanushpolsky, Elena

PURPOSE:

To determine the optimal hCG dose in a dual hCG/GnRH agonist trigger for comparable pregnancy outcomes to hCG, while maintaining low OHSS rates in good-prognosis patients.

SUBJECTS:

This retrospective cohort study included patients aged 18-41 years undergoing IVF or IVF/ICSI with fresh embryo transfer from 2013 to 2024. Patients received either hCG-only (5,000-10,000 IU hCG/250-500 mcg Ovidrel) or dual trigger (1,500-2,000 IU hCG + 2 mg GnRH agonist).

RESULTS:

A total of 2641 cycles were analyzed (1,939 hCG-only, 616 1,500 IU hCG dual trigger, and 86 2,000 IU hCG dual trigger). The 2,000 IU hCG dual trigger group yielded more mature oocytes (16.0 vs. 11.6, aRR 1.29), fertilized embryos (12.9 vs. 8.8, aRR 1.43), and blastocysts (8.0 vs. 4.9, aRR 1.55) than hCG-only. Implantation rates were higher with 2,000 IU hCG dual trigger than hCG-only (50.0% vs. 32.0%, RR 1.56), with a dose-dependent improvement within the dual trigger groups (50.0% at 2,000 IU vs. 36.4% at 1,500 IU, RR 1.37). Ongoing pregnancy rates were similar between 2,000 IU hCG dual trigger and hCG-only (46.8% vs. 39.5%, aRR 1.12), but lower with 1,500 IU hCG dual trigger (46.8% vs. 37.6%, aRR 1.37). OHSS rates were low across all groups.

CONCLUSION:

2,000 IU hCG appears to be the optimal dose in a dual hCG/GnRH agonist trigger, resulting in similar pregnancy outcomes to an hCG trigger and low rates of OHSS among good-responder patients. Ongoing pregnancy rates were significantly lower with hCG doses under 2,000 IU in the dual trigger protocol.

News (Medical) associated with Choriogonadotropin alfa

25 Feb 2026

·www.biospace.com

Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU

White House , screengrab In his State of the Union address on Tuesday evening, President Donald Trump urged Republican leaders to pass legislation cementing his new drug pricing initiatives as he touted his efforts to lower healthcare costs for Americans. President Donald Trump called on Congress to codify his Most Favored Nation drug pricing initiative into law, as he delivered the State of the Union address at the Capitol in Washington, D.C. on Tuesday evening. He also touted his efforts to lower drug prices and the success of deals with pharma companies that were signed over the fall. “Under my just enacted Most Favored Nation agreements, Americans who have for decades paid by far the highest prices of any nation anywhere in the world for prescription drugs will now pay the lowest price anywhere in the world for drugs,” Trump said, according to a transcript of the event. “I took prescription drugs, a very big part of healthcare, from the highest price in the entire world to the lowest. That’s a big achievement.” The White House launched the TrumpRx platform in February , offering select drugs from major pharma companies on a direct-to-consumer basis. Analysts have been skeptical of the program’s ability to lower out-of-pocket costs for patients, as many of the drugs offered were heading for a patent cliff and would be lowered anyway. Other experts also questioned the impact of the program, which would likely only serve uninsured patients or those with high-deductible plans. Most patients would have access to steeper discounts via their regular insurance plans. Pfizer was the first company to sign an MFN deal last year, soon to be followed by the likes of AstraZeneca, Amgen, Bristol Myers Squibb and more. The CEOs of Eli Lilly and Novo Nordisk attended a joint announcement at the White House in November to offer their GLP-1 products, including initial doses of upcoming oral weight loss medicines, for $150. Many of the companies reached the agreements in exchange for exemption from tariffs. Drug pricing How Effective Will TrumpRx and Other Direct-to-Consumer Drug Pricing Initiatives Be? With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those announced to much fanfare from the White House, will result in meaningful reductions in drug spending. November 12, 2025 · 11 min read · Tristan Manalac Read More Trump said the TrumpRx platform has lowered drug prices “300, 400, 500, 600 percent and more.” The president specifically pointed to medicines for in vitro fertilization, which are not typically covered by insurance plans. In October, Merck KGaA’s U.S. subsidiary EMD Serono announced an agreement with the U.S. government to broaden access to its fertility medications, including Gonal-F, Ovidrel and Cetrotide. In his address, Trump called out one patient in attendance who was able to access IVF medications for less, Catherine Rayner. Rayner was the first person to utilize the TrumpRx platform, according to the president. “One drug has been costing Catherine $4,000 to purchase. But a few weeks ago, she logged on to the website and got that same drug that cost costs $4,000, got it for under $500, a reduction of much more actually than $3,500,” Trump said. “Catherine, we are all praying for you and you’re going to be a great mom.” With Rayner as an example, Trump urged his Republican leaders in Congress to codify Most Favored Nation drug pricing. “I’m not sure it matters because it’s going to be very hard for somebody that comes along after me to say, let’s raise drug prices by 700 or 800 percent. But John and Mike, if you don’t mind, codify it anyway,” he said, referring to Senate Majority Leader John Thune and House Speaker Mike Johnson. Trump already urged Congress to address MFN in a January announcement of “The Great Healthcare Plan,” which seeks to take the drug pricing fight to insurers. Drug pricing Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026 Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo. January 6, 2026 · 5 min read · Annalee Armstrong Read More

17 Oct 2025

·www.fiercepharma.com

Merck KGaA's EMD Serono strikes MFN deal in Trump's fertility treatment pricing push

Merck KGaA’s U.S. arm EMD Serono is the latest to join President Donald Trump's most-favored nation pricing push, following AstraZeneca and Pfizer. Merck KGaA’s U.S. arm EMD Serono is joining President Donald Trump’s most-favored nation drug pricing push with an agreement to sell its fertility therapies at a sharp discount through the government’s TrumpRx direct-to-consumer purchasing platform.The company will offer its full in vitro fertilization (IVF) drug portfolio, including Gonal-f, Cetrotide and Ovidrel, to eligible patients, with an 84% discount for the use of all three therapies in a typical IVF regimen when TrumpRx goes live in 2026. Citing the Centers for Medicare & Medicaid Services, the White House said the price cuts could save patients up to $2,200 per IVF cycle. Fertility medications make up almost 20% of the total cost of treatment, which can total between $15,000 and $30,000 for one round, according to GoodRx. The new public-private partnership with EMD Serono complies with Trump’s February executive order on expanding access to IVF, the company said in a Thursday press release. The White House said EMD Serono will offer other drugs at deep discounts when sold directly to patients and guarantee MFN prices on new medicines, while the company separately said it reached a Commerce Department agreement to exclude its products from Section 232 tariffs in return for U.S. manufacturing and research investments.EMD Serono already has a strong U.S. presence and looks “forward to growing our footprint here even further with future fertility manufacturing,” CEO of Merck KGaA, Darmstadt, Germany’s Belén Garijo said in the company's release.“We are committed to working with the U.S. administration to add value over the long term, ensuring that our patients and customers continue to have access to and benefit from the innovations within our portfolio,” Garijo added.According to the White House, the agreement marks the “first time in history” that EMD Serono is investing in U.S. manufacturing. The company has long operated in the U.S. and moved its headquarters to Boston in 2023.EMD Serono’s Gonal-f was first approved in the late 90s as one of the first recombinant human products used to treat infertility. Since then, the Merck KgaA unit has built out its fertility franchise to include other complementary products and devices, with the next addition now coming to the U.S. sooner, with a potential FDA Commissioner’s National Priority Voucher (CNPV).CNPV for IVF The company’s Pergoveris, a combination of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) that’s designed to “mimic reproductive physiology,” will soon be filed for FDA review under its CNPV program. The program applies to products that align with U.S. national health priorities and reduces the FDA’s review timeline from about 10 to 12 months to one to two months. FDA Commissioner Marty Makary, M.D., launched the CNPV program in June and announced the first nine recipients on Oct. 16. Other than EMD Serono’s Pergoveris for infertility, investigational products from Regeneron, Sanofi and others made the cut to treat diseases ranging from diabetes, deafness and blindness, to name a few.Pergoveris is already widely available outside the U.S. If it wins U.S. approval, the White House said patients could benefit further from lower prices thanks to increased competition in the fertility drug market.Along with the administration’s deal with EMD Serono, it announced new guidance for employers to offer standalone benefit packages for IVF and infertility. One in 8 U.S. couples struggles with fertility, according to EMD Serono, which describes itself as “the leader in fertility therapeutics.”EMD Serono joins AstraZeneca and Pfizer in complying with Trump’s MFN pricing demands, which look to tie U.S. prices to lower costs overseas. Much of the deal implores companies to sell their drugs directly to patients, which many have already embraced. Others, like Bristol Myers Squibb, will roll out their drugs in the U.K. at higher U.S.-linked prices.

Drug Approval

17 Oct 2025

·www.pharmaceutical-technology.com

EMD Serono partners US government to widen IVF access

Patients will have access to an expanded network from early 2026 and all EMD Serono’s fertility medications. Credit: MidoSemsem/Shutterstock.com. Merck’s healthcare division in Canada and the US, EMD Serono, has signed an agreement with the Trump administration to expand access to the company’s in vitro fertilisation (IVF) therapies for more than 10 million American women struggling to conceive. EMD Serono agreed to provide direct-to-consumer (DTC) sales of its entire range of IVF therapies, including Ovidrel (choriogonadotropin alfa injection), Cetrotide (cetrorelix acetate for injection) and Gonal-f (follitropin alfa injection), to qualified patients with prescriptions at lower prices. When all three therapies are included in a standard IVF protocol, patients will benefit from an 84% reduction on list prices. EMD Serono is set to take part in the TrumpRx.gov direct purchasing platform, scheduled to launch in January 2026. Patients will have access to an expanded network available from early next year, as well as all of EMD Serono’s fertility medications through the company’s current pharmacy network. This public-private partnership is in accordance with the White House Executive Order aimed at enhancing affordable access to IVF. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence EMD Serono has also reached an agreement with the US Secretary of Commerce to exempt its pharmaceutical products and ingredients from Section 232 tariffs, contingent upon the company’s investment in future biopharmaceutical manufacturing and research in the US. Merck executive board chair and CEO Belén Garijo stated: “We have a strong presence in the US across all three of our business sectors, with a significant number of our employees based in this key market, and look forward to growing our footprint here even further with future fertility manufacturing. “We are committed to working with the US administration to add value over the long term, ensuring that our patients and customers continue to have access to and benefit from the innovations within our portfolio.” In September 2025, Merck and Siemens signed a memorandum of understanding (MoU) to enhance their strategic partnership, aimed at accelerating digital transformation in the life sciences sector. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

100 Deals associated with Choriogonadotropin alfa

External Link

KEGG	Wiki	ATC	Drug Bank
D03478	Choriogonadotropin alfa	G03GA08	DB00097

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anovulation	Australia	Merck Healthcare Pty Ltd.	17 Sep 2003
Infertility, Female	European Union	Merck Europe BV	02 Feb 2001
Infertility, Female	Iceland	Merck Europe BV	02 Feb 2001
Infertility, Female	Liechtenstein	Merck Europe BV	02 Feb 2001
Infertility, Female	Norway	Merck Europe BV	02 Feb 2001
Infertility	United States	EMD Serono, Inc.	20 Sep 2000
Hypogonadism	United States	Fresenius SE & Co. KGaA	05 Mar 1973

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Functional disorder	Phase 3	Japan	Merck KGaA	01 Sep 2012
Hypothalamic Diseases	Phase 3	Japan	Merck KGaA	01 Sep 2012
Polycystic Ovary Syndrome	Phase 3	Japan	Merck KGaA	01 Sep 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01154192 (CTgov)	Phase 3	Polycystic Ovary Syndrome	24	recombinant human chorionic gonadotropin (r-hCG)+Dexamethasone (PCOS Group)	dgnirirwlx(dsuhzpunke) = uibvgryisf ytogdndatk (ebsmwdrywg, 0.5) View more	-	23 Apr 2019
				recombinant human chorionic gonadotropin (r-hCG)+Dexamethasone (Normal Group)	dgnirirwlx(dsuhzpunke) = rpstaqrpwu ytogdndatk (ebsmwdrywg, 0.3) View more
NCT00249834 (CONSORT, CTgov)	Phase 4	Infertility	166	Recombinant human chorionic gonadotrophin (r-hCG)+Gonal-f (Gonal-f 75 IU)	jzfesasdhu(vmsqdgmjsp) = bmszbvrfea elbyxoxfun (behlgdnnjq, 4.5) View more	-	30 Mar 2018
				Recombinant human chorionic gonadotrophin (r-hCG)+Gonal-f (Gonal-f 112.5 IU)	jzfesasdhu(vmsqdgmjsp) = wrmncsisho elbyxoxfun (behlgdnnjq, 6.5) View more
NCT00989781 (CTgov)	Not Applicable	Polycystic Ovary Syndrome	41	Glucose+recombinant human chorionic gonadotropin+Dexamethasone+Adrenocorticotropin+Recombinant human follicle stimulating hormone (Normal Women)	tmnvguntzw(jcxvmgojax) = yyqeorpsmg zvvuwsnxoc (qjwxrbpadt, 0.2) View more	-	17 Oct 2017
				Glucose+recombinant human chorionic gonadotropin+Dexamethasone+Adrenocorticotropin+Recombinant human follicle stimulating hormone (PCOS Women)	tuyzzivyop(ghdvedrjix) = convoastwq qitztrryhy (vtzqmayvmi, mgfjxamjxj - futanrajbe) View more
NCT05321511 (Pubmed \| Reprod Biomed Online)	Phase 4	Adjuvant	156	GnRHa and HCG trigger	ycvitbxthf(kpmlagzdxl) = kksiiytwek jmigpvogzq (hvasockack )	-	01 Nov 2016
				HCG trigger	ycvitbxthf(kpmlagzdxl) = pejfrxxykg jmigpvogzq (hvasockack )
NCT01653743 (CTgov)	Phase 3	Functional disorder \| Polycystic Ovary Syndrome \| Anovulation	81	MSJ-0011+Follitropin alpha	iayrchzpsm = tliqkjstss hdgdnhsqij (wdxggsmugi, qbtjhcdpus - jidlcnzvsh) View more	-	07 Jan 2016
NCT01504139 (Pubmed \| Hum Reprod)	Phase 4	-	93	hCG stimulation (Control group)	dhhrlnhzmf(nofvrecndz) = oqnujayzjp iilisirhjj (mhbrpfiebi )	-	01 Oct 2015
				hCG stimulation (Study group 1)	dhhrlnhzmf(nofvrecndz) = eekftobueo iilisirhjj (mhbrpfiebi )
NCT00328926 (CTgov)	Phase 4	secondary testicular failure	11	Recombinant human chorionic gonadotropin (r-hCG)+Luveris® 75 IU+Recombinant human follicle stimulating hormone (r-hFSH) (Luveris® 75 IU)	kiwmjsohbp(pbselidaoa) = rgxaeagwzv umxjxonrut (hnrzufmsjs, fqqnerrljc - vuivqphuya) View more	-	12 Jul 2013
				Recombinant human chorionic gonadotropin (r-hCG)+Luveris® 25 IU+Recombinant human follicle stimulating hormone (r-hFSH) (Luveris® 25 IU)	kiwmjsohbp(pbselidaoa) = toevewdnyq umxjxonrut (hnrzufmsjs, mbvcagfkzc - yxyfmhczby) View more
NCT00747617 (CTgov)	Phase 3	Polycystic Ovary Syndrome	25	hCG (PCOS)	ecimfommnz(kpnslxyrpn) = pdhrkecrrv yzcszxsndq (dbbjqeepyd, 0.3) View more	-	29 Jan 2013
				hCG (Normal)	ecimfommnz(kpnslxyrpn) = upocxrqwho yzcszxsndq (dbbjqeepyd, 0.1) View more
NCT01210144 (EXPRESS, CTgov)	Phase 4	Infertility, Female \| Infertility \| Infertility, Male	27	Ovitrelle+Gonal-f (Gonal-f® + Ovitrelle®)	pdnbevmdca = nbcjrfhllf togfbhizhv (rrkgnierki, yhiokzawea - nzmecuyysp) View more	-	14 Nov 2012
				Ovitrelle+Gonal-f (Gonal-f® + Ovitrelle® (Long Agonist Protocol))	nvytgomzxv = hnzjjuiyml ryrhlxoljz (fjqytmnamr, iefjpqmdem - hzqqhizbxz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis